false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP05. A Biomarker-Directed, Multi-Center Phase II ...
FP05. A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Elsan Agnostou from Johns Hopkins discusses a trial in progress focusing on biomarker-directed immunochemotherapy in lung cancer. The study utilizes liquid biopsy approaches to analyze ctDNA levels in lung cancer patients undergoing immune checkpoint blockade treatment. The analysis has revealed distinct patterns of ctDNA-based molecular response that align with patients' clinical outcomes. The trial is conducted in two stages, with the first stage enrolling 50 metastatic NMC patients to determine the optimal time point for molecular response. The second stage involves treatment-naive NMC patients receiving Pembrolizumab alone or in combination with chemotherapy based on ctDNA molecular response. The primary endpoints of the trial include determining optimal time points for ctDNA molecular response and validating the concordance of ctDNA response with radiologic response. Secondary and tertiary endpoints include investigating the association of ctDNA response with survival and performing nuanced analysis of ctDNA features. The trial is currently ongoing with 34 out of 50 planned patients enrolled. The ultimate goal is to incorporate liquid biopsies into clinical cancer care and tailor therapies for immunotherapy patients more effectively. The trial is sponsored by the Cancer Research Institute, the Mark Foundation, and Personal Genome Diagnostics.
Asset Subtitle
Valsamo Anagnostou
Meta Tag
Speaker
Valsamo Anagnostou
Topic
Liquid Biopsy and Other Non-invasive Diagnostic Modalities
Keywords
biomarker-directed immunochemotherapy
liquid biopsy
ctDNA levels
immune checkpoint blockade treatment
molecular response
×
Please select your language
1
English
5
普通话
11
Dutch